Lawmakers said to miss mark by delaying biogenerics

10/7/2009 | News & Observer (Raleigh, N.C.), The

Senate and House proposals on biogeneric drugs will hamper competition instead of lowering prices, writes a Duke medical student and member of Universities Allied for Essential Medicines, in this News & Observer opinion piece. The proposals now under review would grant biopharmaceutical companies a 12-year exclusivity on brand-name biologics before their biogeneric counterparts can be approved and marketed, and the branded versions could receive 12-year extensions following slight modifications, she says.

View Full Article in:

News & Observer (Raleigh, N.C.), The